{"id":"conventional-synthetic-dmard","safety":{"commonSideEffects":[{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Conventional synthetic DMARDs (disease-modifying antirheumatic drugs) work by broadly suppressing T-cell and B-cell activation and reducing production of pro-inflammatory cytokines. SetPoint Medical's approach in this class typically involves modulation of immune responses to achieve anti-inflammatory effects. These agents target multiple steps in the inflammatory cascade rather than a single specific molecular target.","oneSentence":"Conventional synthetic DMARDs suppress immune system activity through inhibition of inflammatory pathways to reduce joint inflammation and slow disease progression in rheumatoid arthritis.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:07:46.052Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"}]},"trialDetails":[{"nctId":"NCT05782335","phase":"","title":"Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":72},{"nctId":"NCT07163221","phase":"NA","title":"At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study [At-home ULTRA Study]","status":"RECRUITING","sponsor":"SecondWave Systems Inc.","startDate":"2025-11-03","conditions":"Rheumatoid Arthritis (RA)","enrollment":60},{"nctId":"NCT04539964","phase":"PHASE3","title":"Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"SetPoint Medical Corporation","startDate":"2021-01-11","conditions":"Rheumatoid Arthritis","enrollment":243},{"nctId":"NCT07335952","phase":"PHASE2","title":"Proximod, a Selective Sphingosine-1-phosphate Receptor 1 Modulator in Patients With Moderate-to-severe Active Rheumatoid Arthritis: a Double-blind, Randomised, Placebo-controlled, Phase 2 Trial.","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2024-09-02","conditions":"Rheumatoid Arthritis","enrollment":179},{"nctId":"NCT05671497","phase":"PHASE2, PHASE3","title":"The Effect of Cilostazol on Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":70},{"nctId":"NCT06977035","phase":"NA","title":"Nerve Conduction Study for Assessment of Peripheral Neuropathy in Rheumatoid Arthritis Patients on the Janus Kinase Inhibitor Baricitinib","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2025-05","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT03747939","phase":"PHASE4","title":"Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-12-31","conditions":"Arthritis, Psoriatic","enrollment":310},{"nctId":"NCT03086343","phase":"PHASE3","title":"A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-05-09","conditions":"Rheumatoid Arthritis (RA)","enrollment":657},{"nctId":"NCT03652961","phase":"PHASE4","title":"Rheumatoid Arthritis Memory B Cells and Abatacept","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2019-06-02","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT06306339","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of Burfiralimab (hzVSF-v13) and DMRD (Disease-modifying Antirheumatic Drug)","status":"UNKNOWN","sponsor":"ImmuneMed, Inc.","startDate":"2024-03","conditions":"Moderate to Severe Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT03486457","phase":"PHASE3","title":"Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-08-10","conditions":"Psoriatic Arthritis","enrollment":204},{"nctId":"NCT03970837","phase":"PHASE3","title":"Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-06-05","conditions":"Arthritis, Rheumatoid","enrollment":1764},{"nctId":"NCT04134728","phase":"PHASE3","title":"Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-10-31","conditions":"Arthritis, Rheumatoid","enrollment":550},{"nctId":"NCT02675426","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-17","conditions":"Rheumatoid Arthritis","enrollment":661},{"nctId":"NCT02706847","phase":"PHASE3","title":"A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03-15","conditions":"Rheumatoid Arthritis","enrollment":499},{"nctId":"NCT02476084","phase":"","title":"Biomarker Signature and Musculoskeletal Ultrasound Profile in Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2014-10-13","conditions":"Rheumatoid Arthritis","enrollment":43},{"nctId":"NCT05165771","phase":"PHASE2","title":"Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment","status":"WITHDRAWN","sponsor":"Gilead Sciences","startDate":"2022-07","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT01146652","phase":"PHASE3","title":"Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-06-21","conditions":"Rheumatoid Arthritis","enrollment":2023},{"nctId":"NCT05078502","phase":"NA","title":"Role of Vitamin D3 Supplementation With Conventional Synthetic Disease Modifying Antirheumatic Drugs(csDMARD) in Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2021-06-01","conditions":"Rheumatoid Arthritis","enrollment":58},{"nctId":"NCT02873936","phase":"PHASE3","title":"Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-07-27","conditions":"Rheumatoid Arthritis","enrollment":449}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":98,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Background therapy with conventional synthetic DMARD"],"phase":"phase_3","status":"active","brandName":"Conventional Synthetic DMARD","genericName":"Conventional Synthetic DMARD","companyName":"SetPoint Medical Corporation","companyId":"setpoint-medical-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Conventional synthetic DMARDs suppress immune system activity through inhibition of inflammatory pathways to reduce joint inflammation and slow disease progression in rheumatoid arthritis. Used for Rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}